Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Account Payables (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Account Payables for 12 consecutive years, with $483000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 1625.0% to $483000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $474000.0, a 398.11% increase, with the full-year FY2023 number at $425000.0, up 479.46% from a year prior.
  • Change in Account Payables was $483000.0 for Q3 2025 at Gyre Therapeutics, up from -$51000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.3 million in Q4 2022 to a low of -$3.7 million in Q2 2022.
  • A 5-year average of $66888.9 and a median of -$10000.0 in 2023 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 713.11% in 2021, then surged 1625.0% in 2025.
  • Gyre Therapeutics' Change in Account Payables stood at $2.6 million in 2021, then soared by 144.48% to $6.3 million in 2022, then tumbled by 101.66% to -$104000.0 in 2023, then skyrocketed by 126.92% to $28000.0 in 2024, then soared by 1625.0% to $483000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Account Payables are $483000.0 (Q3 2025), -$51000.0 (Q2 2025), and $14000.0 (Q1 2025).